Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans
Frédéric De Ceuninck1,*, Catherine Kargar1, Catherine Ilic1, Audrey Caliez1, Jean-Olivier Rolin1, Thierry Umbdenstock2, Cédric Vinson3, Murielle Combettes1, Brant de Fanti1, Elizabeth Harley1, Marjorie Sadlo1, Anne-Laure Lefèvre1, Olivier Broux1, Michel Wierzbicki4, Jean-Marie Fourquez4, Françoise Perron-Sierra4, András Kotschy5, Alain Ktorza1
Sources: 1. Division of Metabolic Diseases, Institut de Recherches Servier, Suresnes, France; 2. DMPK Predevelopment, Technologie Servier, Orléans, France; 3. Biopharmaceutical coordination, Technologie Servier, Orléans, France; 4. Division of Medicinal Chemistry, Institut de Recherches Servier, Suresnes, France; 5. Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
DOI: 10.1111/j.1476-5381.2012.02184.x British Journal of Pharmacology,; Accepted manuscript online: 27 AUG 2012 10:08PM EST, Manuscript Accepted: 3 AUG 2012
